Cargando…

Non-Aspergillus mould lung infections

Non-Aspergillus filamentous fungi causing invasive mould infections have increased over the last years due to the widespread use of anti-Aspergillus prophylaxis and increased complexity and survival of immunosuppressed patients. In the few studies that have reported on invasive mould infection epide...

Descripción completa

Detalles Bibliográficos
Autores principales: Puerta-Alcalde, Pedro, Garcia-Vidal, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724803/
https://www.ncbi.nlm.nih.gov/pubmed/36261156
http://dx.doi.org/10.1183/16000617.0104-2022
_version_ 1784844493762068480
author Puerta-Alcalde, Pedro
Garcia-Vidal, Carolina
author_facet Puerta-Alcalde, Pedro
Garcia-Vidal, Carolina
author_sort Puerta-Alcalde, Pedro
collection PubMed
description Non-Aspergillus filamentous fungi causing invasive mould infections have increased over the last years due to the widespread use of anti-Aspergillus prophylaxis and increased complexity and survival of immunosuppressed patients. In the few studies that have reported on invasive mould infection epidemiology, Mucorales are the most frequently isolated group, followed by either Fusarium spp. or Scedosporium spp. The overall incidence is low, but related mortality is exceedingly high. Patients with haematological malignancies and haematopoietic stem cell transplant recipients comprise the classical groups at risk of infection for non-Aspergillus moulds due to profound immunosuppression and the vast use of anti-Aspergillus prophylaxis. Solid organ transplant recipients also face a high risk, especially those receiving lung transplants, due to direct exposure of the graft to mould spores with altered mechanical and immunological elimination, and intense, associated immunosuppression. Diagnosing non-Aspergillus moulds is challenging due to unspecific symptoms and radiological findings, lack of specific biomarkers, and low sensitivity of cultures. However, the advent of molecular techniques may prove helpful. Mucormycosis, fusariosis and scedosporiosis hold some differences regarding clinical paradigmatic presentations and preferred antifungal therapy. Surgery might be an option, especially in mucormycosis. Finally, various promising strategies to restore or enhance the host immune response are under current evaluation.
format Online
Article
Text
id pubmed-9724803
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-97248032022-12-08 Non-Aspergillus mould lung infections Puerta-Alcalde, Pedro Garcia-Vidal, Carolina Eur Respir Rev Series Non-Aspergillus filamentous fungi causing invasive mould infections have increased over the last years due to the widespread use of anti-Aspergillus prophylaxis and increased complexity and survival of immunosuppressed patients. In the few studies that have reported on invasive mould infection epidemiology, Mucorales are the most frequently isolated group, followed by either Fusarium spp. or Scedosporium spp. The overall incidence is low, but related mortality is exceedingly high. Patients with haematological malignancies and haematopoietic stem cell transplant recipients comprise the classical groups at risk of infection for non-Aspergillus moulds due to profound immunosuppression and the vast use of anti-Aspergillus prophylaxis. Solid organ transplant recipients also face a high risk, especially those receiving lung transplants, due to direct exposure of the graft to mould spores with altered mechanical and immunological elimination, and intense, associated immunosuppression. Diagnosing non-Aspergillus moulds is challenging due to unspecific symptoms and radiological findings, lack of specific biomarkers, and low sensitivity of cultures. However, the advent of molecular techniques may prove helpful. Mucormycosis, fusariosis and scedosporiosis hold some differences regarding clinical paradigmatic presentations and preferred antifungal therapy. Surgery might be an option, especially in mucormycosis. Finally, various promising strategies to restore or enhance the host immune response are under current evaluation. European Respiratory Society 2022-10-19 /pmc/articles/PMC9724803/ /pubmed/36261156 http://dx.doi.org/10.1183/16000617.0104-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Series
Puerta-Alcalde, Pedro
Garcia-Vidal, Carolina
Non-Aspergillus mould lung infections
title Non-Aspergillus mould lung infections
title_full Non-Aspergillus mould lung infections
title_fullStr Non-Aspergillus mould lung infections
title_full_unstemmed Non-Aspergillus mould lung infections
title_short Non-Aspergillus mould lung infections
title_sort non-aspergillus mould lung infections
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724803/
https://www.ncbi.nlm.nih.gov/pubmed/36261156
http://dx.doi.org/10.1183/16000617.0104-2022
work_keys_str_mv AT puertaalcaldepedro nonaspergillusmouldlunginfections
AT garciavidalcarolina nonaspergillusmouldlunginfections